Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $43.0K | $1.12M |
| Revenue growth | — | — | — | — | — | 2511.6% |
| Gross profit | — | — | — | — | $43.0K | $796K |
| Gross margin | — | — | — | — | 100.0% | 70.9% |
| Operating income | -$3.20M | -$5.67M | -$9.95M | -$11.4M | -$11.0M | -$12.5M |
| Operating margin | — | — | — | — | -25511.6% | -1114.0% |
| Net income | -$3.80M | -$6.32M | -$9.89M | -$10.2M | -$8.81M | -$11.2M |
| Net margin | — | — | — | — | -20497.7% | -994.5% |
| EPS (diluted) | -$1.72 | -$1.21 | -$1.09 | -$0.99 | -$0.40 | -$0.32 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$3.53M | -$5.92M | -$8.81M | -$10.3M | -$9.13M | -$11.0M |
| Capital expenditures | — | — | — | — | $12.0K | $2.00K |
| Free cash flow | — | — | — | — | -$9.14M | -$11.0M |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.79M | $15.2M | $4.39M | $1.17M | $7.15M | $7.02M |
| Total assets | $1.91M | $16.3M | $7.26M | $1.47M | $8.12M | $8.10M |
| Total liabilities | $4.12M | $938K | $1.10M | $4.47M | $3.64M | $2.67M |
| Shareholders' equity | -$14.7M | $15.3M | $6.16M | $3.00M | $4.48M | $5.42M |
| Retained earnings | -$15.0M | -$21.3M | -$31.2M | -$41.4M | -$50.2M | -$61.4M |
| Shares (wtd avg diluted) | 2.23M | 5.22M | 9.05M | 10.3M | 22.3M | 35.3M |
Every figure is extracted from RenovoRx, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.